Skip to content

Atlas Molecular Pharma, approval for the treatment of Congenital Erythropoietic Porphyria

15 · 03 · 18 - ABGclients - ABG IP

This post is also available in: Español Català

Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), receives approval by the European Commission of Ciclopirox as an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria.

“The favourable report from the European Medicines Agency and the approval of Ciclopirox as OMP by the European Commission are very important steps in the development of Ciclopirox for the treatment of Congenital Erythropoietic Porphyria. “ATLAS will continue with plans for the development of Ciclopirox. The new OMP status will facilitate the process and ultimately contribute to our goal of delivering Ciclopirox to patients suffering from Congenital Erythropoietic Porphyria at the earliest time possible”, said Dr. Emilio Díez, CEO and CSO of Atlas.

ABG IP is proud to collaborate with Atlas Molecular Pharma and CIC bioGUNE in the IP protection of this ciclopirox medicine.

For more information, see the press release issued by Atlas Molecular Pharma.

Go backatlas molecular pharma, approval for the treatment of congenital erythropoietic porphyria